Rosen Law Firm Announces Investigation of China Nuokang Bio-Pharmaceutical In Connection With Going Private Proposal from Kingbird Investment Inc. - NKBP
NEW YORK--(BUSINESS WIRE)-- The Rosen Law Firm is investigating the Board of Directors of China Nuokang Bio-Pharmaceutical Inc. (NAS: NKBP) for possible breaches of fiduciary duty and other violations of corporate law in connection with a going private proposal from Kingbird Investment Inc., beneficially owned by Ms. Yuhuan Zhu - the wife of Nuokang's Chairman and CEO, Mr. Baizhong Xue.
If you would like to join the action please email or call Phillip Kim or Kevin Chan, toll-free, at 866-767-3653; or email at firstname.lastname@example.org or email@example.com. There is no cost or obligation to you.
Under the terms of the proposal, offered by Kingbird Investment, shareholders will receive $5.80 for each American Depository Share ("ADS") or $0.725 for each common share of Nuokang they own. The investigation relates to whether the proposal for $5.80/ADS is fair to public shareholders and whether Nuokang's Board fiduciary duties in connection with the offer.
If you own shares of Nuokang and wish to obtain additional information, you may contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
The Rosen Law Firm P.A.
Phillip Kim, Esq.
Laurence Rosen, Esq.
275 Madison Avenue 34th Floor
New York, New York 10016
Weekends Tel: 917-562-8616
Toll Free: 1-866-767-3653
KEYWORDS: United States North America New York
The article Rosen Law Firm Announces Investigation of China Nuokang Bio-Pharmaceutical In Connection With Going Private Proposal from Kingbird Investment Inc. - NKBP originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.